Class: Antineoplastic Agents
Chemical Name: 4-Amino-1-(2-deoxy-β-d-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
Molecular Formula: C8H12N4O4
CAS Number: 2353-33-5
Brands: Dacogen
Introduction
Antineoplastic agent; a synthetic nucleoside analog of 2′-deoxycytidine.1 3 4 5
Uses for Decitabine
Myelodysplastic Syndrome
Treatment of myelodysplastic syndrome (MDS);1 3 4 designated an orphan drug by FDA for this use.2
Used in patients with previously treated or untreated, de novo or secondary MDS of all French-American-British (FAB) subtypes (i.e., refractory anemia [RA], RA with ringed sideroblasts [RARS], RA with excess blasts [RAEB], RAEB in transformation to leukemia [RAEB-T], chronic myelomonocytic leukemia [CMML]) and International Prognostic Scoring System (IPSS) risk groups with scores of ≥0.5 (i.e., intermediate-1, intermediate-2, and high-risk groups).1 3 4
Decitabine Dosage and Administration
General
Consult specialized references for procedures for proper handling and disposal of antineoplastic drugs.1
Consider premedicating with an antiemetic to prevent nausea and vomiting.1
Administration
IV Administration
For solution compatibility information, see Compatibility under Stability.
Administer by IV infusion.1
Reconstitution
Reconstitute vial containing 50 mg of decitabine with 10 mL of sterile water for injection to provide a solution containing 5 mg/mL.1 3
Dilution
Immediately after reconstitution, dilute appropriate dose in an appropriate volume (e.g., 50–250 mL) of 0.9% sodium chloride, 5% dextrose, or lactated Ringer’s injection to yield a final concentration of 0.1–1 mg/mL.1 3
Dilute reconstituted solutions in cold (2–8°C) compatible IV infusion fluids, unless administration can occur within 15 minutes of reconstitution.1 3 (See Storage under Stability.)
Rate of Administration
Administer by continuous IV infusion over 3 hours.1
Dosage
Withhold therapy if Scr ≥2 mg/dL, serum ALT or total bilirubin concentration ≥2 times the ULN, or if active or uncontrolled infection occurs; delay subsequent cycles until recovery occurs.1 (See Adequate Patient Evaluation and Monitoring under Cautions.)
Adults
Myelodysplastic Syndrome
IV
15 mg/m2 every 8 hours for 3 consecutive days (total dose 135 mg/m2 per treatment cycle) every 6 weeks. 1 3
A minimum of 4 treatment cycles is recommended; however, additional cycles may be needed to achieve a complete or partial response.1 3
Continue treatment as long as the patient is deriving benefit.1 3
Dosage Modification for Hematologic Toxicity
Dosage modification is based on time to hematologic recovery (i.e., ANC ≥1000/mm3, platelet count ≥50,000/mm3) from previous treatment cycle.1
Hematologic recovery >6 to <8 weeks from previous treatment cycle: Delay next treatment cycle up to 2 weeks and temporarily reduce dosage at the start of the next cycle to 11 mg/m2 every 8 hours for 3 consecutive days (total dosage during treatment cycle: 99 mg/m2).1
Hematologic recovery >8 to <10 weeks from previous treatment cycle: Evaluate for disease progression (i.e., by bone marrow aspirates).1 If no disease progression, delay next treatment cycle up to 2 more weeks and reduce dosage to 11 mg/m2 every 8 hours for 3 consecutive days (total dosage during treatment cycle: 99 mg/m2).1 Reduced dosage may be maintained or increased in subsequent treatment cycles as clinically indicated.1
Special Populations
Hepatic Impairment
Routine dosage reduction not required.3
Renal Impairment
Possible decreased elimination; dosage reduction may be necessary.3
Cautions for Decitabine
Contraindications
Known hypersensitivity to decitabine.1
Warnings/Precautions
Warnings
Fetal/Neonatal Morbidity and Mortality
May cause fetal harm; teratogenicity and embryolethality demonstrated in animals.1 Women should avoid pregnancy during therapy; men should not father child during therapy and for 2 months after therapy.1 If used during pregnancy or if patient becomes pregnant during therapy, apprise of potential fetal hazard.1
Major Toxicities
Hematologic Effects
Risk of dose-limiting and potentially fatal myelosuppression, manifested commonly as severe neutropenia, severe thrombocytopenia, and anemia.1 Myelosuppression may occur more frequently in the first and second treatment cycles and may not indicate progression of underlying MDS.1
Delay or reduce dosage for subsequent cycles based on hematologic recovery.1 (See Dosage Modification for Hematologic Toxicity under Dosage and Administration.)
Consider the early use of hematopoietic growth factor and/or anti-infective therapy to prevent or treat complicating infections.1 3
General Precautions
Adequate Patient Evaluation and Monitoring
Perform CBC and platelet counts prior to each treatment cycle and periodically thereafter.1
Monitor liver function tests and Scr prior to each treatment cycle.1 Do not administer to patients with serum ALT or total bilirubin concentrations ≥2 times the ULN or Scr ≥2 mg/dL.1
Specific Populations
Pregnancy
Category D.1 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)
Lactation
Not known whether decitabine is distributed into milk; discontinue nursing or the drug.1
Pediatric Use
Safety and efficacy not established.1
Geriatric Use
Safety and efficacy in those ≥65 years of age similar to that in younger adults; however, increased sensitivity to the drug in some geriatric individuals cannot be ruled out.1
Hepatic Impairment
Not studied in patients with hepatic impairment.1
Use with caution1 and monitor carefully.3 Dosage adjustment not expected to be necessary.3
Renal Impairment
Not studied in patients with renal impairment.1
Use with caution1 and monitor carefully.3 Dosage reduction may be necessary.1
Common Adverse Effects
Neutropenia, thrombocytopenia, anemia, fatigue, pyrexia, nausea, cough, petechiae, constipation, diarrhea, hyperglycemia.1
Interactions for Decitabine
No formal drug interaction studies to date; however, in vitro studies suggest that decitabine is not a substrate for CYP enzymes and is unlikely to inhibit or induce CYP enzymes.1
Decitabine Pharmacokinetics
Distribution
Extent
Following IV administration, decitabine rapidly enters cells by a nucleoside-specific transport mechanism; distributed into body fluids and crosses the blood-brain barrier.5
Plasma Protein Binding
<1%.1
Elimination
Metabolism
Converted intracellularly to an active 5′-triphosphate metabolite.1 5 Also undergoes deamination by cytidine deaminase, principally in the liver, as well as granulocytes, intestinal epithelium, and whole blood.1
Elimination Route
Exact elimination pathways unknown;1 however, decitabine and its metabolites appear to be ultimately eliminated renally.3
Half-life
Biphasic; terminal half-life is approximately 0.51 hour.1
Stability
Storage
Parenteral
Powder for Injection
25°C (may be exposed to 15–30°C).1
Dilute immediately after reconstitution.1 Solutions diluted in cold (2–8°C) infusion fluids may be stored at 2–8°C for up 7 hours.1 Solutions diluted in infusion fluids that are not cold must be used within 15 minutes of reconstitution.1
Compatibility
For information on systemic interactions resulting from concomitant use, see Interactions.
Parenteral
Solution Compatibility
Compatible |
|---|
Dextrose 5% in water1 |
Ringer’s injection, lactated1 |
Sodium chloride 0.9%1 |
ActionsActions
Exert its antineoplastic effect by incorporating into DNA and inhibiting DNA methyltransferase, thereby causing hypomethylation of DNA.1 3 4 5 Does not appear to cause major suppression of DNA synthesis.1
Hypomethylation may restore normal function to genes silenced by aberrant DNA methylation (e.g., tumor suppressor genes) that are critical for cellular differentiation, proliferation, senescence, and apoptosis.1 5
May exert a direct cytotoxic effect by forming covalent adducts with DNA methyltransferase in rapidly dividing cells.1 Nonproliferating cells are relatively insensitive to decitabine.1
Cell-cycle specific, acting principally in the S phase of the cell cycle; does not inhibit progression of cells from G1 into S phase.5
Advice to Patients
Importance of women informing clinicians immediately if they are or plan to become pregnant or plan to breast-feed.1 Advise women to avoid pregnancy during therapy and advise men not to father a child during and for 2 months following discontinuance of therapy.1 Necessity of advising pregnant women of the risk to the fetus.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses (e.g., liver or kidney disease).1
Importance of informing patients of other important precautionary information. (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Parenteral | For injection | 50 mg | Dacogen | MGI Pharma |
Disclaimer
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions May 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
References
1. MGI Pharma, Inc. Dacogen (decitabine) prescribing information. Bloomington, MN; 2006 May.
2. Food and Drug Administration. Orphan designation pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act. (P.L. 97-414). Rockville, MD; From FDA website (). Accessed 2006 Jul 13.
3. MGI Pharma, Inc., Bloomington, MN: Personal communication.
4. Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106:1794-803. [PubMed 16532500]
5. Momparler RL. Pharmacology of 5-Aza-2’-deoxycytidine (decitabine). Semin Hematol. 2005; 42:S9-16. [PubMed 16015507]
6. Kantarjian HM, Issa JP. Decitabine dosing schedules. Semin Hematol. 2005; 42:S17-22.
7. Myelodysplastic syndromes. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 Aug 24.
More Decitabine resources
- Decitabine Side Effects (in more detail)
- Decitabine Use in Pregnancy & Breastfeeding
- Decitabine Drug Interactions
- Decitabine Support Group
- 0 Reviews for Decitabine - Add your own review/rating
- Decitabine MedFacts Consumer Leaflet (Wolters Kluwer)
- Decitabine Professional Patient Advice (Wolters Kluwer)
- decitabine Intravenous Advanced Consumer (Micromedex) - Includes Dosage Information
- Dacogen Prescribing Information (FDA)
- Dacogen Consumer Overview
Compare Decitabine with other medications
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
